• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Olema Pharmaceuticals Inc.

    4/28/25 4:35:04 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OLMA alert in real time by email
    DEFA14A 1 olma-defa14a-2025_notice.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

     

    (Amendment No. )

     

    Filed by the Registrant

    þ

     

    Filed by a Party other than the Registrant

    ☐

     

    Check the appropriate box:

     

     

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    þ

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to § 240.14a-12

    ​

    Olema Pharmaceuticals, Inc.

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box)

     

    þ

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


    img13709071_0.jpg

     

    LOGO Olema oncology ote C 1234567890 ENDORSEMENT_LINE SACKPACK 000001 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 How to Vote Online Go to www.envisionreports.com/OLMA or scan the QR code — login details are located in the shaded bar below. Phone Call toll free 1-800-652-VOTE (8683) within the USA, US territories and Canada Votes submitted electronically and by phone must be received by 11:59 p.m. Eastern Time, on June 9, 2025 Stockholder Meeting Notice 1234 5678 9012 345 Important Notice Regarding the Availability of Proxy Materials for the Olema Pharmaceuticals, Inc. Annual Stockholder Meeting to be Held on June 10, 2025. Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy of the proxy materials. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement and annual report to stockholders are available at: www.envisionreports.com/OLMA Easy Online Access — View your proxy materials and vote. Step 1: Go to www.envisionreports.com/OLMA. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 30, 2025 to facilitate timely delivery. 04599C 2NOT COY


    img13709071_1.jpg

     

    Stockholder Meeting Notice Olema Pharmaceuticals, Inc. Annual Meeting of Stockholders will be held on June 10, 2025 in a virtual format only, live via the Internet at 8:00 a.m. Pacific Time. You will be able to attend the Annual Meeting by first registering at web.viewproxy.com/olma/2025. You will receive a meeting invitation by e-mail with your unique join link along with a password prior to the meeting date. Stockholders will be able to listen, vote and submit questions during the virtual meeting. All registrations to attend the Annual Meeting must be received by 11:59 p.m. Eastern Time on June 6, 2025. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR all the nominees listed under Proposal 1, and FOR Proposals 2 and 3. 1. Election of the three nominees for Class II director named in the accompanying proxy statement to hold office until the Company’s 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. Nominees: 01 - Cynthia Butitta 02 - Cyrus Harmon, Ph.D. 03 - Graham Walmsley, M.D., Ph.D. 2. Approval, on an advisory basis, of the compensation of the Company’s named executive officers. 3. Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025. 4. Any other business properly brought before the meeting. NOTE: Your proxy holder will also vote on any other business properly brought before the meeting or any adjournment or postponement thereof. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/OLMA. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Olema Pharmaceuticals, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. Requests, instructions and other inquiries sent to this email address will NOT be forwarded to your investment advisor. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 30, 2025. There is NO charge for requesting a copy of the voting material(s).


    Get the next $OLMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OLMA

    DatePrice TargetRatingAnalyst
    4/2/2024$24.00Buy
    Goldman
    1/30/2024$20.00Buy
    Citigroup
    7/21/2023$21.00Outperform
    Oppenheimer
    5/5/2023$16.00Overweight
    CapitalOne
    2/22/2023$12.00Outperform
    Credit Suisse
    7/6/2022$16.00Buy
    Canaccord Genuity
    6/9/2022$12.00Neutral → Buy
    H.C. Wainwright
    2/28/2022Neutral
    HC Wainwright & Co.
    More analyst ratings

    $OLMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

      90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to be presented on Monday, June 2 between 9:00am–12:00pm CT / 10:00am–1:00pm ET SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it has aligned with the U.S. Food and Drug Administration (FDA) to select 90 mg of palazestrant as the dose for Part 2 of the ongoi

      5/28/25 7:00:00 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology to Participate in Upcoming Investor Conferences

      SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Jefferies Global Healthcare ConferenceDate and Time: Wednesday, June 4, 2025 at 11:40 a.m. ETFormat: Fireside ChatLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate and Time: Wednesday, June 11, 2025 at 8 a.m. ETFormat: Fireside ChatLocation: Miami, FL Live webcasts and recordings o

      5/21/25 4:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology Reports First Quarter 2025 Financial and Operating Results

      Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ongoing Phase 1b/2 studyPivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer continues to advance with top-line data anticipated in 2026; trial-in-progress poster to be highlighted at ASCO Annual MeetingPreclinical data for OP-3136 presented at AACR demonstrating anti-tumor activity in ovarian, non-small cell lung, and prostate cancer models; Phase 1 trial recruitment ongoingEnded the first quarter with $392.7 million in cash, cash equivalents, and marketabl

      5/13/25 4:01:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Bain Capital Life Sciences Investors, Llc bought $1,727,370 worth of shares (300,000 units at $5.76) and disposed of 3,500,000 shares (SEC Form 4)

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      1/13/25 4:34:40 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) and bought $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

      4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      12/18/24 6:52:04 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      12/17/24 7:52:19 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Olema Pharmaceuticals with a new price target

      Goldman initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $24.00

      4/2/24 7:41:58 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Olema Pharmaceuticals with a new price target

      Citigroup initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $20.00

      1/30/24 7:36:41 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Olema Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Olema Pharmaceuticals with a rating of Outperform and set a new price target of $21.00

      7/21/23 7:55:18 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

      SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

      12/11/24 4:30:15 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

      SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

      12/4/24 7:49:50 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc.

      SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

      11/14/24 4:34:56 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Leadership Updates

    Live Leadership Updates

    See more
    • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w

      3/4/25 4:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

      SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. "We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Her extensive e

      2/18/25 7:00:00 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $OLMA
    Financials

    Live finance-specific insights

    See more
    • Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

      Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With a median follow-up of 12 months, median progression-free survival (PFS) has not been reached6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibitor treatment; data continue to mature Conference call today at 8:00 a.m. ET SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA),

      12/10/24 7:00:00 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

      SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Poster Details Title: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patien

      11/25/24 5:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

      Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted the

      5/15/24 7:01:00 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Olema Pharmaceuticals Inc.

      SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

      5/15/25 3:51:30 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Olema Pharmaceuticals Inc.

      10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

      5/13/25 4:15:24 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

      5/13/25 4:05:11 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Graham G. Walmsley

      4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      5/13/25 7:14:52 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CH. DISCOV. & NON-CLIN DEV OFF Myles David C.

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      3/3/25 4:20:52 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF MEDICAL OFFICER Zojwalla Naseem

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      3/3/25 4:19:32 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care